Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

RATINGS CHANGES

Abbott Laboratories (ABT) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: ABT.

Actuant (ATU) was upgraded to overweight from sector weight at Keybanc. $32 price target. The new CEO is making positive changes and the industrial business appears to be rebounding, Keybanc said. 

IberiaBank (IBKC) was upgraded to outperform from market perform at JMP Securities. $94 price target. Sabadell acquisition will add to earnings, JMP said. 

Ionis Pharma (IONS) was downgraded to sell from neutral at Goldman Sachs. $25 price target. There are questions on the market viability of two products in Phase 3 trials, Goldman said. 

Kimberly-Clark (KMB) was downgraded to hold from buy at Societe Generale. $144 price target. The company is facing increased price competition, Societe said. 

Luminex (LMNX) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: LMNX.

Loxo Oncology (LOXO) was downgraded to neutral at Citigroup. The valuation is less attractive, based on a $45 price target, Citi said. 

Mednax (MD) was downgraded to neutral from overweight at JPMorgan. The valuation is more attractive, based on a $69 price target, JPMorgan said. 

This article was written by a staff member of TheStreet.

If you liked this article you might like

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Alibaba, Qorvo, Abbott Laboratories, Square: 'Mad Money' Lightning Round

Walmart Is One of 63 Companies Contributing Massively to Aid Harvey Relief

Abbott Updates Pacemaker, Defibrillator Software to Protect Against Hacking